• A trial of different treatments for women who have ovarian cancer with BRCA gene faults

Welcome to OCTOVA.

This is a new study providing access to olaparib with or without cediranib to platinum resistant ovarian cancer patients who have BRCA gene mutations. Currently these patients receive treatment with paclitaxel, and OCTOVA will examine whether olaparib with or without cediranib provides a more safe and effective therapy.

Patients will be randomly assigned to receive a) weekly intravenous paclitaxel, b) daily olaparib orally or c) daily olaparib and cediranib orally. Treatment in every group will continue until the patient's doctor feels that the therapy is no longer beneficial. The patients who are randomly assigned to receive intravenous weekly paclitaxel will be able to cross over to oral olaparib treatment once their doctor feels paclitaxel is no longer benefitting them.

LATEST NEWS

Recruitment has been picking up substantially in the last few weeks. We have now recruited participants from eight sites and have passed10% of our final recruitment target (see total number of participants recruited below). A big thank you to all staff at the sites!

Recruitment Progress:
132
16
132
16